Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 0.47 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149470 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL583320 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL4771744 | 0.97 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL8209880 | 0.97 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL649131 | 0.96 | SIGMAR1 (0.50) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL4134315 | 0.96 | SIGMAR1 (0.50) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL23320287 | 0.95 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL980555 | 0.95 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL3415840 | 0.95 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Bromide SCHEMBL22800758 | 0.94 | SIGMAR1 (0.43) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057931-A | Temperature response polymer material with iridium complex and europium chelate as monomers, and preparation method and application thereof | 南京工业职业技术大学 | 2022-02-18 | — | — | CN | claimed |
| CN-110357828-B | Nuclear magnetic resonance contrast agent and preparation method and application thereof | 牡丹江医学院 | 2021-03-19 | — | — | CN | claimed |
| US-12466843-B2 | Gadolinium-based compound, method for producing same, and MRI contrast agent containing same | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-11-11 | — | — | US | disclosed |
| US-12384802-B2 | Manufacturing of dimeric contrast agent | BRACCO IMAGING S.P.A. (IT) | 2025-08-12 | — | — | US | disclosed |
| EP-4377323-B1 | MANUFACTURING OF DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| US-12290576-B2 | Manufacturing of dimeric contrast agents | BRACCO IMAGING S.P.A. (IT) | 2025-05-06 | — | — | US | disclosed |
| US-20240425527-A1 | MANUFACTURING OF DIMERIC CONTRAST AGENT | BRACCO IMAGING S.P.A. (IT) | 2024-12-26 | — | — | US | disclosed |
| US-20240269330-A1 | MANUFACTURING OF DIMERIC CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2024-08-15 | — | — | US | disclosed |
| EP-4188912-B1 | MANUFACTURING OF DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2024-07-03 | — | — | EP | disclosed |
| CN-114845998-B | Preparation of protected DO3A | 伯拉考成像股份公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4377323-A1 | MANUFACTURING OF DIMERIC CONTRAST AGENTS | Bracco Imaging SPA (IT) | 2024-06-05 | — | — | EP | disclosed |
| US-20070154732-A1 | Dendrimer compound and organic luminescent device employing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-0755269-B1 | CONTRAST AGENTS | AMERSHAM HEALTH SALUTAR INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-0722442-B1 | POLYAZACYCLOALKANES AS DICHELANTS | NYCOMED SALUTAR INC (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6010681-A | CHELATE COMPOUND | NYCOMED SALUTAR, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5972307-A | ADMINISTERING TO HUMAN OR ANIMAL BODY AN EFFECTIVE AMOUNT OF A DIAGNOSTIC AGENT COMPRISES A METAL CHELATE OF A COMPOUND HAVING TWO MACROCYCLIC CHELANT GROUPS LINKED BY A BRIDGE CONTAINING ESTER OR AMIDE BOND | NYCOMED SALUTAR, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5650133-A | CHELATING AGENTS USEFUL IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS | NYCOMED SALUTAR (US) | 1997-07-22 | — | — | US | disclosed |
| EP-0755269-A1 | CONTRAST AGENTS | NYCOMED SALUTAR, INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028967-A1 | CONTRAST AGENTS | NYCOMED SALUTAR INC (US) | 1995-11-02 | — | — | WO | disclosed |
| WO-1995009848-A2 | POLYAZACYCLOALKANES AS DICHELANTS | NYCOMED SALUTAR, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384802-B2 | Manufacturing of dimeric contrast agent | KCNK4, HK1, KCNK10 | SIGMAR1 2665/4885CHRM3 3455/4885CHRM2 1658/4885 |
| US-12290576-B2 | Manufacturing of dimeric contrast agents | MGAT3, MGAT2, MGAT1 | SIGMAR1 1309/4885CHRM3 3929/4885CHRM2 2416/4885 |
| US-20240269330-A1 | MANUFACTURING OF DIMERIC CONTRAST AGENTS | MGAT3, MGAT2, MGAT1 | SIGMAR1 1309/4885CHRM3 3929/4885CHRM2 2416/4885 |
| US-12466843-B2 | Gadolinium-based compound, method for producing same, and MRI contrast agent containing same | RXFP1, NMRAL1, MEN1 | SIGMAR1 4452/4885CHRM3 3521/4885CHRM2 2900/4885 |
| US-20240425527-A1 | MANUFACTURING OF DIMERIC CONTRAST AGENT | KCNK4, HK1, KCNK10 | SIGMAR1 2665/4885CHRM3 3455/4885CHRM2 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.